Oral N-acetylcysteine for Retinitis Pigmentosa
Studying Retinitis pigmentosa
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Peter A Campochiaro, MDJohns Hopkins University
- Intervention
- N-acetylcysteine(drug)
- Enrollment
- 485 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2030
Study locations (30)
- University of California - Davis, Department of Ophthalmology & Vision Science, Davis, California, United States
- University of Southern California, Keck School of Medicine, Los Angeles, California, United States
- University of California - San Francisco, Department of Ophthalmology, San Francisco, California, United States
- Stanford University, Byers Eye Institute, Stanford, California, United States
- Vitreo Retinal Associates, Gainesville, Florida, United States
- University of Florida - Jacksonville, UF Health Jacksonville, Jacksonville, Florida, United States
- University of Miami, Bascom Palmer Eye Institute, Miami, Florida, United States
- Emory University, Emory Eye Center, Atlanta, Georgia, United States
- University Of Illinois At Chicago, Chicago, Illinois, United States
- Northwestern University, Evanston, Illinois, United States
- University of Iowa, Carver College of Medicine, Iowa City, Iowa, United States
- Wilmer Eye Institute- Johns Hopkins University, Baltimore, Maryland, United States
- Harvard University, Mass. Eye and Ear, Boston, Massachusetts, United States
- University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan, United States
- University of Minnesota, Department of Ophthalmology and Visual Neurosciences, Minneapolis, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Eye Institute (NEI) · Duke University · Emory University · Massachusetts Eye and Ear Infirmary · Mayo Clinic · Medical College of Wisconsin · Retina Foundation of the Southwest · Stanford University · University of California, Davis · University of Florida · University of Iowa · University of Miami · University of Michigan · University of Minnesota · University of Oklahoma · University of Southern California · University of Utah · University of Washington · University of Wisconsin, Madison · Vanderbilt University · Vitreo Retinal Associates, PA · University of Houston · Medical University of Graz · McGill University · Universität Tübingen · Radboud University Medical Center · University of Amsterdam · University Hospital, Basel, Switzerland · University College London Hospitals · Northwestern University · University of Pennsylvania
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05537220 on ClinicalTrials.govOther trials for Retinitis pigmentosa
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)Ray Therapeutics, Inc.
- RECRUITINGNANCT07292987Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts HospitalCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- RECRUITINGNANCT07266584Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationScience Corporation
- RECRUITINGNCT07228793Natural History Study of Patients With EYS-Associated RPSensor Technology for Deafblind
- RECRUITINGPHASE1, PHASE2NCT06891885A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaSumitomo Pharma America, Inc.
- RECRUITINGPHASE2NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaBeacon Therapeutics
- RECRUITINGPHASE2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT06912633Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)jCyte, Inc